A Phase 3b, Prospective, Randomized, Open-label, Blind Evaluator (PROBE) Study Evaluating the Efficacy and Safety of (LMW) Heparin/Edoxaban Versus Dalteparin in Venous Thromboembolism Associated With Cancer

Trial Profile

A Phase 3b, Prospective, Randomized, Open-label, Blind Evaluator (PROBE) Study Evaluating the Efficacy and Safety of (LMW) Heparin/Edoxaban Versus Dalteparin in Venous Thromboembolism Associated With Cancer

Completed
Phase of Trial: Phase III

Latest Information Update: 14 Feb 2018

At a glance

  • Drugs Edoxaban (Primary) ; Dalteparin sodium
  • Indications Deep vein thrombosis; Pulmonary embolism; Venous thromboembolism
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms Hokusai-VTE Cancer
  • Sponsors Daiichi Sankyo Inc
  • Most Recent Events

    • 15 Dec 2017 Results published in the Servier Canada Media Release
    • 12 Dec 2017 Primary endpoint (Incidence of of clinically relevant bleeding while on treatment) has been met, according to a Daiichi Sankyo media release.
    • 12 Dec 2017 Results published in the New England Journal of Medicine.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top